Overcoming the limitations of traditional antibody discovery methods, our groundbreaking fully human single domain antibody platform harnesses the power of genetically engineered mice to create a highly efficient and sustained development approach. Partner with us to gain access to an unprecedentedly powerful and cutting-edge platform to accelerate the discovery and development of novel therapeutics.
Advantages of Single Domain Antibodies
Single domain antibodies (sdAbs), also known as VHH antibodies or camelid antibodies, are heavy chain antibodies (HCAbs) that naturally lack light chains and are found in camelids and cartilaginous fish. Unlike conventional antibodies, sdAbs possess a single monomeric variable domain that retains antigen-binding capabilities. This unique structure confers several advantages that make sdAbs a promising tool in biotechnology and therapeutics.
Small Size and Better Tissue Penetration
Due to their single-domain nature, sdAbs are approximately half the size of traditional antibodies, making them more accessible to target antigens. This smaller size allows it to better penetrate tissue, including solid tumors or the blood-brain barrier.
High Stability and Strong Affinity
The absence of a light chain in sdAbs reduces the likelihood of aggregation and increases their resistance to harsh conditions. The longer CDR3 of sdAbs compensates for the lack of a light chain and maintains strong antigen binding.
Diverse Target Recognition and Specificity
Through their variable domains, sdAbs can bind to unique epitopes on antigens with high affinity, enabling precise target recognition. Moreover, their small size allows access to cryptic or conformational epitopes that may be inaccessible to larger antibodies.
Low Immunogenicity and Easy to Modify
sdAbs have small molecular weight and fewer epitopes that bind to antigens, so they have low immunogenicity. sdAbs can be modified through genetic manipulation techniques to optimize their pharmacokinetic properties, increase their serum half-life, or confer other functions.
GeniusAb™ : Fully Human Single Domain Antibody Platform
To mitigate the expenses and time associated with discovering novel therapeutic single domain antibodies from species like camels and sharks, our company has developed an innovative solution: GeniusAb™ mice, which are genetically engineered to produce fully human single domain antibodies. By utilizing these mice, we eliminate the need for in vitro humanization, resulting in a more efficient and cost-effective process.
Overview of GeniusAb™ Mice
GeniusAb™ mice express fully human heavy-chain-only antibodies (HCAbs) without the need for in vitro humanization. This unique feature allows for the direct generation of fully human sdAbs, eliminating the potential immunogenicity associated with non-human frameworks.
Advantages of GeniusAb™ Mice
Normal B Cell Development and Differentiation
GeniusAb™ mice have been engineered to ensure the proper maturation and functionality of B cells, allowing for the generation of diverse and functional antibody repertoires.
Exhibit Robust Immune Responses to Multiple Antigens
GeniusAb™ mice exhibit robust immune responses to a wide range of antigens, enabling the generation of antibodies against various targets. These mice possess a diverse repertoire of B cells capable of recognizing and responding to different antigens, including proteins, peptides, and pathogens.
Sequence Diversity and Optimal Affinity
Through the introduction of human antibody gene segments and genetic modifications, GeniusAb™ mice possess a diverse pool of antibody sequences that closely resemble those found in humans. This diversity allows for the exploration of a vast range of antibody variants, increasing the chances of identifying antibodies with optimal affinity and specificity for the target of interest.
Excellent Developability
Antibodies derived from GeniusAb™ mice exhibit desirable characteristics such as stability, solubility, low immunogenicity, and compatibility with downstream manufacturing processes. These attributes are crucial for successfully developing and commercializing antibody-based therapeutics or diagnostics.Comparison of Global Single Domain Antibody Platforms
| Company Name | sdAb Platform | Features | |
| Competitor 1 | Platform 1 | Ultra-large fragment chromosome engineering technology SUPCE-in situ replacement technology, long and time-consuming process | |
| Competitor 2 | Platform 2 | Humanization technology of genome fragments from hundreds of KB to megabytes, non-human antibodies | |
| Competitor 3 | Platform 3 | Ultra-large fragment cross-species in situ replacement technology (MASIRT), non-human antibodies, high cost | |
| Competitor 4 | Platform 4 | HCAb immune cell adapter platform, few VH genes, lack of antibody diversity | |
| Competitor 5 | Platform 5 | Few VH genes, lack of antibody diversity | |
| GeniusAb™ | GeniusAb™ Mouse Platform |
|
|
Optimal Single Domain Antibody Types
- Monovalent single domain antibodies
- Bivalent single domain antibodies
- Bispecific single domain antibodies
- Multivalent single domain antibodies
- Fused single domain antibodies
- And More
Applications
With our fully human single domain antibody development platform, we can provide comprehensive diagnostic reagents and therapeutic drug development services to fully realize the application value of single domain antibodies.
Diagnostic Reagent Development
Taking advantage of the specificity and high affinity of single domain antibodies (sdAbs) for antigens, we develop sdAbs as diagnostic reagents to detect specific biomarkers associated with various diseases. Especially in tumor diagnosis, we use sdAbs labeled with radioactive elements or fluorescent dyes as imaging agents to determine the distribution of tumors in patients.
Table. 1 Diseases suitable for diagnosis with sdAbs
| Infectious Diseases | Autoimmune Diseases | Cancer |
|
|
|
| Neurological Disorders | Cardiac Diseases | Allergies |
|
|
|
Therapeutics Development
Our company is at the forefront of therapeutic drug development, leveraging the unique properties of single domain antibodies (sdAbs) to create targeted and effective therapeutics for a variety of diseases. We develop sdAbs therapeutics for central nervous system diseases, circulatory diseases, infectious diseases, oncology, and inflammatory diseases. We are particularly good at the development of cancer drugs and delivery vectors to promote targeted therapies of cancer and avoid drug side effects.
Targeted Therapy Drug Development
sdAbs can be engineered to specifically recognize and bind to cancer cell surface markers or antigens. By conjugating sdAbs with toxic payloads or linking them to immune effector molecules, they can deliver targeted therapy directly to cancer cells, minimizing damage to healthy tissues.
Immunotherapy Drug Development
sdAbs can enhance the immune response against cancer cells. sdAbs can be used for the identification and therapeutic inactivation of checkpoint inhibitors, activation of antigen presenting cells (APCs), blockade of immunosuppressive cells, neutralization of immunosuppressive molecules, CAR-T or CAR-NK therapy, cytokine regulation, etc.
Drug Delivery Vector Development
sdAbs can serve as carriers for delivering therapeutic payloads to cancer cells. They can be engineered to bind to specific receptors or transporters expressed on cancer cells, facilitating the targeted delivery of chemotherapeutic drugs, radionuclides, or nanoparticles to the tumor site.
Our Advantages
Time-saving services with high efficiency
Professional and experienced team
Cutting edge technology platform
Numerous service cases and customer praise
Our company aims to revolutionize the field of antibody-based therapeutics, providing unparalleled solutions for the development of next-generation biologics. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
References
- Tillib, S. V. "Prospective applications of single-domain antibodies in biomedicine." Molecular Biology 54 (2020): 317-326.
- Wu, Yanling, Shibo Jiang, and Tianlei Ying. "Single-domain antibodies as therapeutics against human viral diseases." Frontiers in immunology 8 (2017): 1802.